1-12 of 12
Witold Rybka
Close
Sort by
Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Claudio G. Brunstein, Paul V O'Donnell, Brent R. Logan, Luciano J. Costa, Corey Cutler, Michael Craig, William J Hogan, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, John M. Magenau, Adriana Malone, John M McCarty, Joseph P. McGuirk, Lawrence E Morris, Andrew R. Rezvani, Witold Rybka, Rachel Salit, Sumithira Vasu, Mary Eapen, Ephraim J. Fuchs
Journal: Blood
Blood (2021) 138 (Supplement 1): 3956.
https://doi.org/10.1182/blood-2021-145527
Published: 2021
Journal Articles

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

Robert J. Soiffer, MD, Haesook T. Kim, PhD, Joseph McGuirk, DO, Mitchell E. Horwitz, MD, Laura Johnston, MD, Mrinal M Patnaik, MBBS, Witold Rybka, MD, Andrew Artz, MD, David L Porter, MD, Thomas C. Shea, MD, Michael W Boyer, MD, Richard T. Maziarz, MD, Madan H. Jagasia, MD, Paul J. Shaughnessy, MD, Usama Gergis, MD, Hana Safah, MD, Ran Reshef, MD, John F. DiPersio, MD PhD, Patrick J. Stiff, MD, Madhuri Vusirikala, MD, Jeff Szer, MB, BS, FRACP, Jennifer Holter, MD, James D. Levine, MD, Paul J. Martin, MD, Joseph A. Pidala, MD, Ian D. Lewis, MBBS PhDFRACP FRCPA, Vincent T. Ho, MD, Edwin P. Alyea, MD, Jerome Ritz, MD, Frank Glavin, Peter Westervelt, MD PhD, Yi-Bin Chen, MD
Journal: Blood
Blood (2016) 128 (22): 505.
https://doi.org/10.1182/blood.V128.22.505.505
Published: 2016
Journal Articles

Tipifarnib As Maintenance Therapy in Acute Myeloid Leukemia (AML) Improves Survival in a Subgroup of Patients with High Risk Disease. Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Victoria X Wang, Elisabeth Paietta, PhD, Rhett P. Ketterling, MD, Witold Rybka, MD, Hillard M. Lazarus, MD, Mark R Litzow, MD, Jacob M. Rowe, MD, Richard A. Larson, MD, Frederick R Appelbaum, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2015) 126 (23): 1308.
https://doi.org/10.1182/blood.V126.23.1308.1308
Published: 2015
Journal Articles

Early Discharge and Out Patient Management After AML Induction Chemotherapy: Determinants of Safety

Roberto A Ferro, MD, Junjia Zhu, Ph.D, W. Christopher Ehmann, MD, Susan Rokita, CRNP, MSN, Vicki Haight, CRNP, MSN, Jo Ann Davidson, CRNP, MSN, Constance Berk, PA-C, Witold Rybka, MD, David F. Claxton, MD
Journal: Blood
Blood (2012) 120 (21): 2054.
https://doi.org/10.1182/blood.V120.21.2054.2054
Published: 2012
Journal Articles

R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Selina Luger, MD, Lynette Zickl, MS, Elisabeth Paietta, PhD, Rhett P Ketterling, MD, Hillard M Lazarus, MD, Witold Rybka, MD, Mark R Litzow, MD, Jacob M Rowe, MD, Richard A. Larson, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2012) 120 (21): 676.
https://doi.org/10.1182/blood.V120.21.676.676
Published: 2012
Journal Articles

Tipifarnib Is Well Tolerated as Maintenance Therapy In Acute Myeloid Leukemia (AML). Significant, but Non-Fatal, Hematologic Toxicity Not Ameliorated by Dose Reduction. Preliminary Results of the Phase III Intergroup Trial E2902

Selina Luger, MD, Xiaopan Yao, PhD, MS, Elisabeth Paietta, PhD, Rhett Ketterling, Witold Rybka, MD, Mark R. Litzow, MD, Jacob M. Rowe, Richard Larson, M.D., Martin S. Tallman, MD
Journal: Blood
Blood (2010) 116 (21): 3315.
https://doi.org/10.1182/blood.V116.21.3315.3315
Published: 2010
Journal Articles

Clofarabine, Etoposide and Mitoxantrone In the Therapy of Relapsed and Refractory Acute Myelogenous Leukemia

W. Christopher Ehmann, MD, Sulfikar Ibrahim, MD, Witold Rybka, MD, David F. Claxton, MD
Journal: Blood
Blood (2010) 116 (21): 4353.
https://doi.org/10.1182/blood.V116.21.4353.4353
Published: 2010
Journal Articles

Sirolimus for Graft-Versus-Host-Diseases Prophylaxis in Non-Myeloablative Matched Related Transplantation: Safety and Efficacy.

Hong Zheng, MD, PhD, Michelle Carraher, BA, Eric Schaefer, M.A., Giampaolo Talamo, MD, W. Christopher Ehmann, MD, Witold Rybka, David F. Claxton, M.D.
Journal: Blood
Blood (2009) 114 (22): 4329.
https://doi.org/10.1182/blood.V114.22.4329.4329
Published: 2009
Journal Articles

G-CSF Mobilized Versus Conventional Donor Lymphocytes in the Treatment of Hematological Malignancies.

Kamal K.S. Abbi, M.D., W. Chritopher Ehmann, MD, Giampaolo Talamo, MD, Kenneth Lucas, MD, Michelle Carraher, BA, Witold Rybka, M.D., David F. Claxton
Journal: Blood
Blood (2009) 114 (22): 4301.
https://doi.org/10.1182/blood.V114.22.4301.4301
Published: 2009
Journal Articles

Single Autologous Stem Cell Transplant Using Busulfan and Cyclophosphamide as Conditioning Regimen in Patients with Multiple Myeloma

Giampaolo Talamo, MD, David F. Claxton, MD, Joseph Drabick, MD, David W. Dougherty, MD, Jeff Sivik, PharmD, Christopher W. Ehmann, MD, Witold Rybka, MD
Journal: Blood
Blood (2008) 112 (11): 4436.
https://doi.org/10.1182/blood.V112.11.4436.4436
Published: 2008
Journal Articles

Non-Myeloablative Hematopoietic Transplant with Sirolimus Immunosuppression: Determinants of Outcome.

David F. Claxton, MD, Chuancai Wang, PhD, Michelle Carraher, Christopher Ehmann, MD, Witold Rybka, MD
Journal: Blood
Blood (2005) 106 (11): 5462.
https://doi.org/10.1182/blood.V106.11.5462.5462
Published: 2005
Journal Articles

Successful Treatment of Advanced and Refractory AML with Sirolimus Based Non-Myeloablative Allogeneic Stem Cell Transplantation.

David F. Claxton, M.D., Christopher Ehmann, M.D., Witold Rybka, M.D.
Journal: Blood
Blood (2004) 104 (11): 2760.
https://doi.org/10.1182/blood.V104.11.2760.2760
Published: 2004